HEREDITARY BREAST AND OVARY CANCER SYNDROME

Is the Public Health System prepared for proper management?

Authors

DOI:

https://doi.org/10.61229/mpj.v1i2.14

Keywords:

Breast Neoplasms, genetic counseling, genetic testing, Mastectomy, Gynecological cancer

Abstract

Around 10% of breast cancer cases and 20% of ovarian cancer cases are associated with a hereditary syndrome. Access to the diagnosis of genetic alterations is still limited in the Public Health System (SUS), despite the constant lowering in the cost of tests. The care system for patients with hereditary cancer is practically non-existent in the public sector in the state of Minas Gerais and breast MRI screening is not available, nor is prophylactic bilateral mastectomy, even though there is a state law guaranteeing the right to this care. The cost-effectiveness of genetic diagnosis is well established and we urgently need to structure oncogenetics services in the various regions of the state.

Downloads

Download data is not yet available.

References

Santos M de O, Lima FC da S de, Martins LFL, Oliveira JFP, Almeida LM de, Cancela M de C. Estimativa de Incidência de Câncer no Brasil, 2023-2025. Revista Brasileira de Cancerologia. 2023 Feb 6;69(1). DOI: https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700

Adam MP, Mirzaa GM, Pagon RA. Associated Hereditary Breast and Ovarian Cancer. 1998.

Qin Z, Kuok CN, Dong H, Jiang L, Zhang L, Guo M, et al. Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population. J Med Genet [Internet]. 2021;58(9):587–91. Available from: https://jmg.bmj.com/content/58/9/587 DOI: https://doi.org/10.1136/jmedgenet-2020-107181

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205–10. DOI: https://doi.org/10.1073/pnas.1415979111

dos Santos Borges R dos S, Silva LG, Vilaca M do N, De Carvalho AR, Solar Vasconcelos JP, Penna Coutinho LF, et al. Prevalence of germline testing criteria in breast cancer patients in the Brazilian public health system: A retrospective study. Journal of Clinical Oncology [Internet]. 2021 May 20;39(15_suppl):10597. Available from: https://doi.org/10.1200/JCO.2021.39.15_suppl.10597 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.10597

Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P. Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Global Oncol [Internet]. 2020;6:439–52. Available from: https://ascopubs.org/go/authors/open-access DOI: https://doi.org/10.1200/JGO.19.00170

Koldehoff A, Danner M, Civello D, Rhiem K, Stock S, Müller D. Systematic Literature Review Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review. Value Health [Internet]. 2021;24(2):303–12. Available from: https://doi.org/10.1016/j.jval.2020.09.016 DOI: https://doi.org/10.1016/j.jval.2020.09.016

Lourenção M, Simões Correa Galendi J, Galvão H de CR, Antoniazzi AP, Grasel RS, Carvalho AL, et al. Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country. Front Oncol. 2022 Jul 11;12. DOI: https://doi.org/10.3389/fonc.2022.951310

Scheffer M, Gil Alves Guilloux A, Alonso Miotto B, de Jesus Almeida C, Guerra A, Cassenote A, et al. Demografia Médica no Brasil 2023 [Internet]. Scheffer M, editor. São Paulo: FMUSP, AMB; 2023. 344. Available from: https://amb.org.br/

Minas Gerais. Lei no. 23449 de 24 de outubro de 2019, Diário do Executivo. Belo Horizonte: Poder Executivo; Oct 25, 2019 p. 1–1.

Downloads

Published

2023-11-30

How to Cite

Brandão, F., & Nogueira Rodrigues, A. (2023). HEREDITARY BREAST AND OVARY CANCER SYNDROME: Is the Public Health System prepared for proper management?. Mário Penna Journal, 1(2), 57–63. https://doi.org/10.61229/mpj.v1i2.14

Issue

Vol. 1 No. 2 (2023): Mário Penna Journal

Section

Artigos

License

Copyright (c) 2023 Mário Penna Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Autores que publicam nesta revista concordam com os seguintes termos:

  • Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
  • Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
  • Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).

Ficheiro:Cc-by-nc-sa icon.svg – Wikipédia, a enciclopédia livre

A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional